Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood tests and surveys may predict cancer treatment success

NCT ID NCT04776837

Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 159 people with metastatic colorectal, pancreatic, biliary, or esophageal cancers who were starting a new line of therapy. Researchers collected blood samples (tumor markers and liquid biopsies) and patient-reported quality-of-life data to see if these could predict how well the treatment worked at the first scan. The goal was to find better ways to track disease progression and response without relying solely on imaging.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict how well a cancer treatment is working early on, using simple blood tests and patient surveys.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to any immediate changes in care, and the results might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

159 people

The number who actually took part.

Started

May 2019

Finished

Oct 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients must have histologically confirmed colorectal, pancreatobiliary, or esophagogastric cancer and receiving anti cancer treatment at Massachusetts General Hospital Cancer Center

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion Criteria: * Patients must have histologically confirmed colorectal, pancreatobiliary, or esophagogastric cancer. * Diagnosed with metastatic disease * Age \> 18 years. * Patients must be starting new line of anti-cancer therapy. * Patient must be English-speaking. * Exclusion Criteria * Unwilling or unable to participate in the study * Non-metastatic disease * Not starting new anti-cancer treatment * Cognitive issues interfering with ability to participate. * Active, unstable, untreated serious mental illness interfering with ability to participate. * Patient does not speak English.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary tract cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms colorectal cancer colorectal neoplasm Disease Progression esophageal cancer Esophageal Neoplasms exocrine pancreatic carcinoma gastroesophageal cancer malignant pancreatic neoplasm metastatic malignant neoplasm Neoplasm Metastasis pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biliary tract cancer Colorectal cancer Disease progression Esophageal cancer Metastatic cancer Pancreatic cancer Patient reported outcome measures Survival analysis

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.